{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for fludrocortisone root_notes_note in Note (approximate match)
Status:
US Previously Marketed
Source:
LUTREPULSE KIT by FERRING
(1989)
Source URL:
First approved in 1978
Source:
NADA098379
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Gonadorelin is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens. The pulsatility of GnRH secretion has been seen in all vertebrates, and it is necessary to ensure a correct reproductive function. Thus a single hormone, GnRH, controls a complex process of follicular growth, ovulation, and corpus luteum maintenance in the female, and spermatogenesis in the male. Its short half life requires infusion pumps for its clinical use. Gonadorelin is used for the treatment of amenorrhea, delayed puberty, and infertility the administration of gonadorelin is used to simulate the physiologic release of GnRH from the hypothalamus in treatment of delayed puberty, treatment of infertility caused by hypogonadotropic hypogonadism, and induction of ovulation in those women with hypothalamic amenorrhea. This results in increased levels of pituitary gonadotropins LH and FSH, which subsequently stimulate the gonads to produce reproductive steroids.
Status:
Possibly Marketed Outside US
Source:
NCT02333591: Phase 4 Interventional Completed Coronary Microvascular Dysfunction
(2016)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00613964: Phase 4 Interventional Terminated Heart Failure
(2009)
Source URL:
Class:
PROTEIN
Carperitide is a synthetic, recombinant atrial natriuretic peptide with both vasodilating and diuretic activity that was developed by Asubio Pharma and used in Japan for acute heart failure treatment. Although the current Japanese Society of Cardiology guidelines for treatment of acute heart failure (AHF) make a class IIa recommendation for Carperitide, a recent meta-analysis and retrospective study revealed that Carperitide could not improve survival rates and was rather associated with a more than double in-hospital mortality rate in patients with AHF.
Status:
Possibly Marketed Outside US
Source:
NCT00720902: Phase 4 Interventional Terminated Growth Hormone Deficiency
(2007)
Source URL:
Class:
PROTEIN
Somatorelin is 29 amino acid analogue of human growth hormone-releasing hormone used as a diagnostic agent for determining growth hormone deficiency. Growth-hormone-releasing hormone (GHRH, somatoliberin) is the hypothalamic peptide hormone that specifically stimulates synthesis and release of growth hormone (GH, somatotropin) by somatotrope cells of the anterior pituitary gland. The hypothalamic hormone growth hormone (GH)-releasing hormone (GHRH) acts on specific GHRH receptors (GHRH-R) in the anterior pituitary gland to stimulate the synthesis and secretion of GH and to promote somatotrope expansion. Somatorelin is applied to determine the somatotropic function of the anterior pituitary gland in cases of suspected growth hormone deficiency. The test distinguishes between pituitary and hypothalamic disorders but is not suitable as a screening test for growth hormone deficiencies. Somatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.
Status:
Excipient
Class:
POLYMER
Status:
Excipient
Source:
9.2mg ORAL TABLET, EXTENDED RELEASE
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Other
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 343
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 343
Source URL:
Class:
POLYMER